No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Dong-A Socio Holdings Co., Ltd., established in Seoul, South Korea in 1932, maintains a prominent role in the pharmaceutical industry both within South Korea and globally. Its diverse product range includes well-known items such as Bacchus, Benachio, and Tempo, alongside various infection management solutions and advanced imaging equipment like the FX-V1 and CLS-S7, which are utilized for surgical and diagnostic purposes. Beyond healthcare, the company offers a selection of beverages, including Gayasan Cheonnyeonsu mineral water, POCARI SWEAT, Narangd cider, Oronamin C, and Oran-C bio-PET. Demonstrating a commitment to innovation, Dong-A Socio Holdings is also developing an mRNA-based COVID-19 vaccine, STP2104, which is currently undergoing Phase I clinical trials. The company provides a wide array of services, encompassing business management, contract manufacturing (CMO) for antibodies and recombinant proteins through pre-clinical studies, clinical trials, and commercial production. Other services include maintenance, repair, and operation (MRO), quarantine, military logistics, and packaging and parcel delivery. They also operate MEDIFLIX, a platform dedicated to medical knowledge-sharing. Furthermore, Dong-A Socio Holdings is engaged in the construction of various industrial facilities, such as biotechnology, pharmaceutical, food production, and logistics warehouses, as well as educational, research, commercial, and public infrastructure. This includes comprehensive design, maintenance, and asset development services. Their capabilities also extend to IT systems, providing both development and maintenance solutions.

• Aarti Drugs Limited
• Unichem Laboratories Limited
• Guizhou Yibai Pharmaceutical Co., Ltd.
• ASKA Pharmaceutical Holdings Co.,Ltd.
• Gufic Biosciences Limited
• Blau Farmacêutica S.A.
• Verano Holdings Corp.
• Elite Pharmaceuticals, Inc.